Business
Appointment of non-Board Interim CFO
Appointment of non-Board Interim CFO.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n9 May 2025\nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\", or the \"Company\")\nAppointment of non-Board Interim CFO\nOndine Biomedical Inc. (AIM: OBI) announces the appointment of Alan Thomas as non-Board interim Chief Financial Officer (CFO) of the Company, effective immediately. Mr. Thomas succeeds Michael Behlke, who is stepping down from his role as CFO and COO for personal reasons. Ondine extends its sincere appreciation to Mr. Behlke for his contributions and wishes him the very best for the future.\nMr. Thomas is a highly accomplished financial executive with more than 25 years of leadership experience across public and private organizations in the healthcare, biotechnology, and infrastructure sectors, from high-growth start-ups to large multinational and public sector organizations. His prior roles include CFO at Maximus Canada Inc., a division of NYSE-listed Maximus Inc., and BC Transit, as well as Head of Finance at BC Emergency Health Services. He has also served as CFO and financial consultant to emerging and growth-stage firms including Aspreva Pharmaceuticals, Aurinia Pharmaceuticals, and Geno 10X, where he played key roles in fundraising, valuation, investor relations, and IPO preparation, notably during Aspreva's public listing.\n \nThroughout his career, Mr. Thomas has provided strategic financial leadership and driven performance improvements through capital planning and enterprise-wide transformation initiatives. His experience includes managing large-scale budgets, implementing integrated business systems (including ERP platforms), and delivering operational efficiencies through procurement modernization and other enterprise initiatives.\n \nMr. Thomas will apply his deep experience in financial strategy, governance, and planning to support Ondine's next phase of growth and the continued expansion of its light-activated antimicrobial technology in key markets.\n \nAlan Thomas, interim CFO of Ondine Biomedical, commented:\n\"Ondine is entering an exciting phase of development, with growing momentum behind its breakthrough technology. I'm looking forward to working with the team to help drive the Company's strategic and financial objectives forward.\"\nCOO duties will be assumed by current executive management.\n \nEnquiries:\n\n\n\n\nOndine Biomedical Inc.\n\n\nwww.ondineb...